India Ratings affirms Nectar Lifesciences’ long-term issuer rating at ‘A-’

26 Apr 2013 Evaluate

India Ratings & Research has affirmed Nectar Lifesciences’ long-term issuer rating at ‘A-’ with stable outlook.

The affirmation reflects the rating agency’s opinion that the company’s financial leverage (adjusted debt net cash/EBITDA) will see a sustained improvement over the medium term after deteriorating to 4.1x in FY12 (financial year ended March) from 3.3x in FY11.

Nectar Lifesciences is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms.

Nectar Lifesciences Share Price

37.76 0.74 (2.00%)
14-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1768.75
Dr. Reddys Lab 1337.30
Cipla 1448.00
Lupin 2155.25
Zydus Lifesciences 1000.80
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.